Brought to you by 
Series C round brings in $15.5mm for Bonti
28 Mar 2018
Executive Summary
Bonti Inc. (neurotoxins for aesthetic and therapeutic indications) closed a $15.5mm Series C financing round from undisclosed new and returning investors. The 2015 start-up will use the proceeds for market research and to fund continued development of lead compound EB001 (botulinum neurotoxin serotype E), including completion of an ongoing Phase II study in musculoskeletal pain and preparation for an end-of-Phase II meeting with the FDA. To date the company has brought in $36.1mm through investors including RBV Capital, City Hill Ventures, Colt Ventures, JMCR Partners, and HighLight Capital.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings in $15.5mm for Bonti
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice